ACM
BHVN

Atika Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Atika Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-75,000
Closed -$2.96M – 112
2018
Q2 		$2.96M Buy
+75,000
New +$2.38M 0.57% 66

Other funds holding BHVN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Atika Capital Management's BHVN Position: Q2 2021 in Review

Atika Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2021, closing a stake of 47,000 shares — an estimated $3.21M sold.

Atika Capital Management first reported a position in BHVN in Q1 2019 and held it in 9 quarters. The position peaked at $12.3M in Q4 2020. 223 funds tracked by Wall St. Rank hold BHVN as of Q2 2021.

  • Atika Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2021 after selling out during the quarter.
  • Atika Capital Management sold 47,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2021, an estimated $3.21M.
  • Atika Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 9 quarters.
  • Atika Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $12.3M in Q4 2020.
  • 223 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2021.

Based on Atika Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.